Marriott A E, Dagley J L, Hegde S, Steven A, Fricks C, DiCosty U, Mansour A, Campbell E J, Wilson C M, Gusovsky F, Ward S A, Hong W D, O'Neill P, Moorhead A, McCall S, McCall J W, Taylor M J, Turner J D
Department of Tropical Disease Biology, Centre for Drugs and Diagnostics, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, United Kingdom.
TRS Laboratories Inc, Athens, GA, United States.
Front Microbiol. 2023 Jun 22;14:1208301. doi: 10.3389/fmicb.2023.1208301. eCollection 2023.
Dirofilariasis, including heartworm disease, is a major emergent veterinary parasitic infection and a human zoonosis. Currently, experimental infections of cats and dogs are used in veterinary heartworm preclinical drug research.
As a refined alternative heartworm preventative drug screen, we assessed lymphopenic mouse strains with ablation of the interleukin-2/7 common gamma chain (γc) as susceptible to the larval development phase of .
Non-obese diabetic (NOD) severe combined immunodeficiency (SCID)γc (NSG and NXG) and recombination-activating gene (RAG)2γc mouse strains yielded viable larvae at 2-4 weeks post-infection, including the use of different batches of infectious larvae, different isolates, and at different laboratories. Mice did not display any clinical signs associated with infection for up to 4 weeks. Developing larvae were found in subcutaneous and muscle fascia tissues, which is the natural site of this stage of heartworm in dogs. Compared with propagated larvae at day 14, derived larvae had completed the L4 molt, were significantly larger, and contained expanded endobacteria titres. We established an L4 paralytic screening system whereby assays with moxidectin or levamisole highlighted discrepancies in relative drug sensitivities in comparison with reared L4 . We demonstrated effective depletion of by 70%-90% in L4 following 2- to 7-day oral exposures of NSG- or NXG-infected mice with doxycycline or the rapid-acting investigational drug, AWZ1066S. We validated NSG and NXG mouse models as a filaricide screen by treatments with single injections of moxidectin, which mediated a 60%-88% reduction in L4 larvae at 14-28 days.
Future adoption of these mouse models will benefit end-user laboratories conducting research and development of novel heartworm preventatives via increased access, rapid turnaround, and reduced costs and may simultaneously decrease the need for experimental cat or dog use.
恶丝虫病,包括犬心丝虫病,是一种主要的新发兽医寄生虫感染病和人畜共患病。目前,猫和犬的实验性感染被用于兽医心丝虫临床前药物研究。
作为一种改进的替代心丝虫预防药物筛选方法,我们评估了白细胞介素-2/7共同γ链(γc)缺失的淋巴细胞减少小鼠品系对恶丝虫幼虫发育阶段的易感性。
非肥胖糖尿病(NOD)严重联合免疫缺陷(SCID)γc(NSG和NXG)以及重组激活基因(RAG)2γc小鼠品系在感染后2至4周产生了存活的恶丝虫幼虫,包括使用不同批次的感染性幼虫、不同的恶丝虫分离株以及在不同实验室进行实验。小鼠在长达4周的时间内未表现出任何与感染相关的临床症状。在皮下和肌肉筋膜组织中发现了发育中的幼虫,这是犬心丝虫此阶段在自然宿主体内的寄生部位。与第14天繁殖的幼虫相比,衍生幼虫已完成L4蜕皮,明显更大,且内共生菌滴度更高。我们建立了一个恶丝虫L4麻痹筛选系统,通过该系统,与饲养的L4相比,莫昔克丁或左旋咪唑的检测突出了相对药物敏感性的差异。在用强力霉素或快速作用的研究性药物AWZ1066S对NSG或NXG感染的小鼠进行2至7天口服暴露后,我们证明恶丝虫L4中的虫体有效减少了70%至90%。通过单次注射莫昔克丁进行治疗,介导了14至28天L4幼虫数量减少60%至88%,我们验证了NSG和NXG小鼠模型可作为杀丝虫剂筛选模型。
未来采用这些小鼠模型将使进行新型心丝虫预防药物研发的终端用户实验室受益,因为它们具有更多的可及性、更快的周转速度、更低的成本,并且可能同时减少对实验用猫或犬的需求。